- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01356563
Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients
Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study
The investigators propose that pharmacist interventions would reduce the amount of unresolved medication-related problems in hemodialysis patients.
Condition:Hemodialysis patients
Intervention:Behavioral,Pharmacist intervention
Study Design:Randomized Allocation
Control: Active Control
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Introduction:
End stage renal disease (ESRD) incidence in Taiwan ranked first and prevalence ranked second in the world from 2002 to 2005. Several foreign researches had reported that hemodialysis (HD) patients often require 12 medications to treat 5 to 6 comorbid conditions. Besides, ESRD is a lifelong disease and rates of compliance may diminish overtime. Thus, HD patients may be at particular risk for drug related problems, durg-drug interactions and noncompliance. Our aim is to analysis the effect of pharmacist in medication-related problems in ambulatory hemodialysis patients.
Methods:
This study is a randomized double-blind, active controlled trial. The investigators will invite and communicate with HD patients to find medication -related problems. After pharmacist evaluation, pharmacist will do pharmaceutical interventions to resolve medication-related problems, drug-drug interactions etc. in experimental group. In the active control group, pharmacist in this study will not do pharmaceutical interventions. The investigators will monitor each patient in a two-week period for medication-related problems.
Our primary outcome is the amount of unresolved medication-related problems in each group after two weeks. Blind outcome assessor will evaluate the amount of unresolved medication-related problems in each case as well as compliance in these patients after two weeks.
The investigators suppose that clinical pharmaceutical intervention will reduce the amount of unresolved medication-related problem in experimental group. On the other hand, patients without clinical pharmaceutical intervention will have more unresolved medication-related problems.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Tainan, Taiwan, 701
- Har ikke rekruttert ennå
- Sin-Lau hospital
-
Ta kontakt med:
- Hung-Yi Chen, MS
- Telefonnummer: 1040 06-2748316
- E-post: lawrence_chern@yahoo.com.tw
-
Ta kontakt med:
- Li-Pin Chou, MD
- Telefonnummer: 5175 06-2748316
- E-post: slh10@sinlau.org.tw
-
Hovedetterforsker:
- Hung-Yi Chen, MS
-
Tainan city, Taiwan
- Rekruttering
- Tainan Sin-Lau Hospital
-
Ta kontakt med:
- Hung-Yi Chen, MS
- Telefonnummer: 1040 06-2748316
- E-post: lawrence_chern@yahoo.com.tw
-
Ta kontakt med:
- Li-Pin Chou, MD
- Telefonnummer: 5175 06-2748316
- E-post: slh10@sinlau.org.tw
-
Hovedetterforsker:
- Hung-Yi Chen, MS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 20-96 years old hemodialysis patient taking medications prescribed by nephrologists.
Exclusion Criteria:
- Patients who refused informed consent
- Cognitive impaired
- unable to talk or hearing disability
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: clinical pharmacist intervention
|
Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
|
Ingen inngripen: usual care
Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
amount of unsolved medication-related problems in each group
Tidsramme: 14 days
|
Clinical pharmacist provide pharmaceutical care in experimental group in order to reduce medication-related problems.
With pharmaceutical care, we suppose that amount of unsolved medication-related problems will less than the control group.
|
14 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Patient self-reported medication compliance
Tidsramme: 14 days after recruitment
|
14 days after recruitment, outcome assessor will record patient self-reported medication compliance. 1 score means almost noncompliance,while 5 score means that patient takes almost every medication.
|
14 days after recruitment
|
pharmaceutical care satisfaction
Tidsramme: 14 days after recruitment
|
From 1 score to 5 scores, 1 score means that patient is very unsatisfied with pharmaceutical care in the past 14 days.
5 scores means that patient is very satisfied with pharmaceutical care in the past 14 days.
|
14 days after recruitment
|
adverse events
Tidsramme: 14 days after recruitment
|
An adverse event is any adverse change in health or side effect that occurs in a person who participates in our clinical trial while the patient is receiving the medications prescribed by physician.
|
14 days after recruitment
|
knowledge about medication
Tidsramme: 14 days after recruitment
|
Patient self-reported knowledge about medication.
From 1 score to 5 scores, as the score increase, it means that patients know more information about his medication.
|
14 days after recruitment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Hung-Yi Chen, Sin-Lau hospital
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Yang WC, Hwang SJ; Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008 Dec;23(12):3977-82. doi: 10.1093/ndt/gfn406. Epub 2008 Jul 15.
- Schmid H, Schiffl H, Lederer SR. Pharmacotherapy of end-stage renal disease. Expert Opin Pharmacother. 2010 Mar;11(4):597-613. doi: 10.1517/14656560903544494.
- Manley HJ, Bailie GR, Grabe DW. Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm. 2000 May 1;57(9):902-6. doi: 10.1093/ajhp/57.9.902. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SLH-100-05
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på pharmaceutical care
-
Centre Hospitalier Universitaire de NīmesFullførtEldret | Sykehusinnleggelse | PasientinnleggelseFrankrike
-
Shuqun ChengUkjentHepatocellulært karsinomKina
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekrutteringPlasmacelleleukemi | Residiverende/refraktært myelomatoseKina
-
The Third Xiangya Hospital of Central South UniversityHar ikke rekruttert ennåCharcot-Marie-Tooth Disease (CMT)
-
Southeast University, ChinaChinese Academy of SciencesFullførtSepsis | Septisk sjokk | Samfunnservervet lungebetennelseKina
-
yongjun wangFullført
-
Bellicum PharmaceuticalsSuspendertHER2-positiv brystkreft | HER2-positiv magekreft | Solid svulst, voksen | HER-2 genamplifikasjon | HER-2 Protein OverekspresjonForente stater
-
Nexcella Inc.Har ikke rekruttert ennåLettkjede (AL) amyloidoseForente stater
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTilbakefallende og refraktær B-celle lymfomKina
-
University of California, San FranciscoTilbaketrukketLymfom | Leukemi | Plasmacelledyskrasi